Skip to main content

Table 1 Distribution of patients per treatment strategy and number of cycles

From: Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study

  Treatment
DOX 75 (N = 948) DOX 50—IFO 5 (N = 614) DOX 75—IFO 5 (N = 266) DOX 75—IFO 10 (N = 217) Total (N = 2045)
Number of patients with at least 6 cycles 403 (42.5) 270 (44.0) 103 (38.7) 118 (54.4) 895 (43.7)
Progression before/at end of treatment 67 (16.6) 55 (20.4) 15 (14.6) 9 (7.6 146 (16.3)
No progression before/at end of treatment 336 (83.4) 215 (79.6) 88 (85.4) 109 (92.4) 748 (83.6)
Number of patients with less than 6 cycles 545 (57.4) 344 (56.0) 163 (61.3) 99 (45.6) 1151 (56.3)
Progression before/at end of treatment 312 (57.2) 175 (50.9) 52 (31.9) 28 (28.3) 567 (49.3)
No progression before/at end of treatment 233 (42.8) 168 (49.1) 111 (68.1) 71 (71.7) 584 (50.7)